Kintor Pharmaceutical Limited released its 2025 Environmental, Social and Governance (ESG) Report, detailing a 6.5% year-on-year decline in total Scope 1 and Scope 2 greenhouse-gas (GHG) emissions to 2,816.25 tonnes of CO₂-equivalent. The drop mainly reflected lower electricity and natural-gas use as headcount fell to 123 employees.

The company consumed 4,781.59 MWh of energy, 33,507 m³ of water and 0.15 tonne of packaging materials during the year. Hazardous waste generation fell to 18.30 tonnes, while non-hazardous waste decreased to 0.74 tonne. A 1-to-2 percent GHG-intensity reduction target has been set for 2026, supported by measures such as HVAC optimisation, equipment efficiency upgrades and expanded waste-recycling initiatives.

Kintor’s ESG governance is led by the board, with execution by an ESG working group drawing members from environment, health and safety, engineering, production, procurement and investor-relations teams. Climate-related oversight now forms part of risk management, and scenario analysis highlights potential regulatory and physical-risk impacts on R&D, supply chain and energy costs.

On the social front, the workforce comprised 59% women and 41% men; turnover was 14.43%. All staff received training, averaging 42 hours per employee. No work-related fatalities occurred in the past three years, and annual medical check-ups plus an institutional animal care committee underpin workplace and research-ethics safeguards.

Supply-chain monitoring covers 2,530 suppliers—about 75% located in Jiangsu, Shanghai and Beijing—and integrates ESG criteria, including anti-bribery requirements. No corruption cases, child labour or forced-labour incidents were reported, and no product-safety recalls or customer-privacy breaches occurred in 2025.

Kintor plans to enhance energy accounting, set science-based reduction targets and explore carbon-neutral pathways over the next decade while advancing dermatology-focused R&D and expanding its cosmetic-ingredients business.